Everything below concerns Telomerase. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-10. Numbers and descriptions here follow the published literature rather than marketing material.
Human data are limited to small studies, often without the randomization, blinding, or control groups expected in contemporary clinical research. Reported outcomes have included changes in melatonin levels, immune markers, and subjective measures, but sample sizes were generally too small to support firm conclusions. Some reviews treat the peptide as promising while noting methodological weaknesses; others question whether the observed effects are specific. The compound is frequently discussed in longevity-focused communities, where enthusiasm often outpaces the published evidence. Separating established findings from speculation is therefore important when reading summaries of this research.
Epitalon emerged from research conducted in Saint Petersburg by Vladimir Khavinson and colleagues, who studied short peptides as potential regulators of aging. The work built on epithalamin, a pineal gland extract reported to influence neuroendocrine function. Epitalon was designed as a synthetic counterpart with a defined sequence, allowing reproducible experiments that extracts could not support. Early publications described effects on melatonin rhythms and lifespan in animal models. These findings circulated mainly in Russian-language journals during the 1990s, which limited their visibility among English-speaking researchers.
The most widely cited claim is that epitalon activates telomerase and thereby extends telomere length. Supporting evidence comes largely from cultured human cells, where treatment was associated with increased telomerase activity and delayed replicative senescence. Telomerase activation is a biologically consequential effect, since the enzyme is largely silenced in most somatic cells. However, the route by which a short peptide would reach and act on the enzyme's regulatory machinery has not been established. Independent replication in human trials is scarce, so the link between cell-culture observations and whole-body aging remains an open question.
Identity and purity are checked by reversed-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, where the peptide bond absorbs. Mass spectrometry confirms the expected mass and reveals whether truncation products or adducts are present. Acid hydrolysis followed by amino acid analysis gives the residue ratio, which should approximate one alanine, one glutamate, one aspartate and one glycine. Counter-ions such as acetate or trifluoroacetate remain in the dried product and lower net peptide content, so a stated purity figure on a label does not by itself describe how much peptide a vial holds.
Regulatory treatment differs by country. No formulation of epitalon holds a marketing authorisation as a medicine in the United States or the European Union, where material sold for laboratory use is handled as a research chemical and is not intended for human consumption. In Russia, several short peptide preparations from the same institute's peptide series are registered medicinal products, and epitalon appears in that national context. Elsewhere it is frequently offered as a cosmetic ingredient, a category with lighter requirements. Advertising claims about longevity or disease prevention are restricted in most jurisdictions, which limits how sellers describe the compound.
Freeze-dried epitalon is normally kept at minus twenty degrees Celsius in a sealed, desiccated container, protected from light. Short excursions at ambient temperature during shipping are generally tolerated, but repeated warming and cooling cycles encourage moisture uptake, which shortens shelf life. Once dissolved, the peptide is far less stable than the solid: aqueous solutions are subject to hydrolysis and to deamidation at the aspartate and glutamate residues. Working solutions are therefore held refrigerated and used within days, and repeated freezing and thawing of the same vial is best avoided.
| Property | Value | Notes |
|---|---|---|
| Peptide sequence | Ala-Glu-Asp-Gly | Single-letter form AEDG |
| Compound class | Synthetic tetrapeptide | Not a natural free peptide |
| Research origin | Russian gerontology institutes | Developed during the 1990s |
| Main research claim | Telomerase activation | Evidence mainly from cultured cells |
| Regulatory status | Not an approved drug | Handled as a research material |
The most frequently cited laboratory finding is that AEDG increased telomerase activity and extended telomere length in cultured human somatic cells. That work used fetal fibroblast strains and reported changes in enzyme activity alongside altered division counts. Replication by unrelated groups has been limited, and the published record is largely a single-laboratory series rather than a multi-centre programme. The result supports a hypothesis about peptide influence on gene expression in cell culture; it does not by itself establish an effect on telomere length in living animals or in people.
Animal and clinical reports appear mainly in Russian-language journals from the 1990s and 2000s, covering endpoints such as melatonin rhythm, lifespan in aged rodents, and retinal function. Many of these papers involve small groups, lack blinding or placebo comparison, and are difficult to retrieve through indexed databases. Review articles published in English generally summarise the claims without reanalysing the underlying data. Because no large randomised trial exists, the clinical importance of these reported effects stays unresolved and is properly described as an open question.
Epitalon appears in the literature primarily through a small number of research groups, most of them associated with the St. Petersburg Institute of Bioregulation and Gerontology. Publications describe cell culture experiments, animal studies, and a limited number of small human studies. Independent replication outside this network is sparse. As a result, reviews of the topic usually separate descriptive reports of observed effects from the question of whether those effects generalize, and they note the difficulty of comparing studies that use different preparations and endpoints.
Analytical characterization of epitalon relies on standard peptide methods. Reverse-phase high-performance liquid chromatography is used to assess purity, and mass spectrometry confirms identity by checking the observed mass against the expected value near 390 daltons. Amino acid analysis can verify composition. Because the peptide is short and hydrophilic, it elutes early on many reverse-phase columns, so method development often requires ion-pairing reagents to achieve adequate retention and resolution from related impurities.
Storage and handling follow conventional peptide practice. Lyophilized epitalon is typically kept refrigerated or frozen, protected from moisture and light, and allowed to equilibrate to room temperature before opening to avoid condensation. Once dissolved, aqueous solutions are usually stored cold and used within a short period, since dilute peptide solutions can support microbial growth and may slowly degrade. The absence of cysteine and methionine reduces, but does not eliminate, oxidation concerns during long-term storage.
Because epitalon has no pharmacopoeial monograph, quality assessment depends on supplier documentation and independent testing. Certificates of analysis typically report a purity figure from a single chromatographic run, a measured mass and sometimes an appearance description, but methods and acceptance criteria are not harmonised across vendors. Third-party laboratories can repeat identity and purity measurements, and mismatches between labelled and measured peptide content have been described for research peptides generally. What constitutes adequate identity confirmation for a molecule of this size stays an open question, since mass agreement alone does not separate closely related sequences.
Identity testing for epitalon relies on reversed-phase high-performance liquid chromatography for purity and mass spectrometry for mass confirmation. Because the sequence contains no tryptophan or tyrosine, ultraviolet detection at 280 nanometres is insensitive, so chromatographic methods usually monitor absorbance near 214 nanometres, where the peptide backbone absorbs. Electrospray ionisation or matrix-assisted laser desorption/ionisation then checks the intact mass against the expected value near 390 daltons. Peptide mapping or amino acid analysis after acid hydrolysis can supplement these measurements, although such confirmatory work is seldom reported on commercial certificates of analysis.
Stability of the tetrapeptide follows ordinary peptide chemistry rather than any unusual structural feature. The aspartate-glycine pair is prone to aspartimide formation under mildly basic or neutral conditions, and deamidation can follow, altering both mass and chromatographic retention. Dry lyophilised powder kept at or below minus twenty degrees Celsius is the usual handling recommendation, with repeated freeze-thaw cycles avoided. Once dissolved in neutral aqueous buffer, degradation proceeds over days to weeks depending on pH and temperature, while acidic conditions generally slow the aspartimide route. A formal stability-indicating study has not been published in the indexed literature.
Stability depends strongly on pH, temperature and the presence of oxygen and trace metals. Cleavage of the backbone proceeds faster under neutral to alkaline conditions, whereas acidic solutions tend to slow that reaction. The aspartate and glutamate side chains can undergo deamidation or imide formation over time, generating closely related impurities. Published stability data specific to epitalon are sparse, so the usable life of a given solution is best regarded as an open question that depends on buffer composition, concentration and storage temperature.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection, frequently near 214 nanometers where the peptide bond absorbs. Mass spectrometry, most often with electrospray ionization, confirms the observed molecular mass and helps separate the intact peptide from truncated or modified forms. Amino acid analysis or tandem mass spectrometry can establish residue order. Purity is commonly quoted as an area percentage, yet such values are method-dependent, and comparisons between laboratories require matching column, gradient and detection wavelength.
=== Gelator === Gelators serve as stabilizers and thickeners, thickening the gel solution while simultaneously maintaining the gel's flexible nature. When dispersed through the solvent as a colloid, gelators offer a stable internal structure to the gel. Gelators are usually chosen based on their affinity for the solvent and the purpose of the gel. The nature of the gelators used determines the rigidity of the gel. There are many types of gelators, of which carbomers are more frequently used due to their ability to thicken gels across a wide range of pH. Gelators can be classified by polymer types, namely natural, semi-synthetic and synthetic polymers. Natural gelators include tragacanth, gelatin, collagen, and guar gum; semi-synthetic gelators include methylcellulose and other cellulose derivatives; while synthetic gelators include carbomers, polyvinyl alcohol, polyethylene and its copolymers.
Bone marrow transplant (heme-oncology intervention): The replacement of the bone marrow with bone marrow from an individual without spherocytosis. The transplanted progenitor cells do not have the genetic mutations found in individuals with hereditary spherocytosis, and therefore do not produce spherocytes. This results in an individual with biconcave-disc-shaped erythrocytes. This treatment is not standard of care, and is not offered as it has only been documented incidentally during treatment for other diseases, such as myelodysplastic syndrome. Symptomatic treatments:
Additionally, PELs lack the inherent amplification capabilities of DELs and rely on current mass spectrometric analysis for decoding. Since peptide decoding requires complex mass spectrometry and computational power, this means that current detection sensitivity limits practical PEL sizes.
== Clinical significance == A genetic association study of four large extended Malay families reported that a decrease in COL21A1 copy number (reduced gene dosage) co-segregated with nonsyndromic cleft lip and/or palate, identifying COL21A1 (together with TOX3) as a candidate susceptibility gene for the condition. This is a single primary study, and a causal role for COL21A1 in cleft lip/palate has not been established.
Sources: en.wikipedia.org
This was Merck's first use of the designation and the reduction in regulatory risk was one of the reasons management was willing to put company resources into development. In 2013, the United States Adopted Name (USAN) name was changed from lambrolizumab to pembrolizumab. In that year clinical trial results in advanced melanoma were published in The New England Journal of Medicine. This was part of the large phase I NCT01295827 trial. In September 2014, the US Food and Drug Administration (FDA) approved pembrolizumab under the Fast Track Development Program. It is approved for use following treatment with ipilimumab, or after treatment with ipilimumab and a BRAF inhibitor in advanced melanoma patients who carry a BRAF mutation. As of 2015, the only PD-1/PD-L1 targeting drugs on the market are pembrolizumab and nivolumab. By April 2016, Merck applied for approval to market the drug in Japan and signed an agreement with Taiho Pharmaceutical to co-promote it there. In July 2015, pembrolizumab received marketing approval in the European Union. In October 2015, the US FDA approved pembrolizumab for the treatment of metastatic non-small cell lung cancer (NSCLC) in people whose tumors express PD-L1 and who have failed treatment with other chemotherapeutic agents. In July 2016, the US FDA accepted for priority review an application for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) after a platinum-based chemotherapy.
Eastern tribes in the mainland US also traded tobacco as a trade item in exchange for food, clothing, beads, and salt, and would often smoke tobacco during sacred and ritualized ceremonies using pipes. Tobacco was considered to be a gift from the gods and it was believed that the exhaled tobacco smoke generated from smoking a pipe would carry one's thoughts and prayers to the creator up above in the heavens. Toboggan – the Innu and the Cree nations of Canada developed a sled in the form of the toboggan. These sleds were used to transport people and cargo across the snow using dogs as draft animals. Sled dogs such as Huskies were used to pull the dog sled along the harsh Canadian winter snows. Toggling harpoon – first used by the Red Paint People of the North American east coast, they were later used by the Thule. Tomato – indigenous Americans were the first peoples in the world to domesticate and cultivate the tomato by 500 BCE. The tomato was an essential ingredient that formed the basis of many indigenous foods including tamales, tostado, soups, and salads. Tomahawk - created originally by the Algonquian people before the arrival of Europeans, the Tomahawk would then later spread from the Algonquian culture to tribes in the South and Great Plains. Tortillas – this staple food well known today was used throughout Mesoamerican and Southwestern US cultures. Although they were mainly made of corn, squash and amaranth were also popular. The tortillas were wrapped around different fillings such as avocado.
that the physical action of crosslinking brings the ectodomain into such a conformation that is required for intracellular tyrosine phosphorylation events to ensue (i.e. these events serve as the requirements for receptor activation and eventual maintenance of blood glucose homeostasis). Visualization of full length IR complexes is not yet available due to many constraints. Visualization of full length IR–insulin complexes is not yet available due to flexible link of transmembrane (TM) domains with extracellular domain and intracellular domain. The transmembrane (TM) domains are critical for activation and downstream signaling. Stabilization of TM domains may be result of phosphatidylinositol. Meanwhile, visualization of full length IR–downstream proteins is challenging because of transient nature of association, the phosphorylation receptor requirement, and the unfixed relative orientation. Applying cryo-EM and molecular dynamics simulations of receptor reconstituted in nanodiscs, the structure of the entire dimeric insulin receptor ectodomain with four insulin molecules bound was visualized, therefore confirming and directly showing biochemically predicted 4 binding locations.
Sources: en.wikipedia.org
Vladimir Khavinson and colleagues at research institutes in Saint Petersburg developed and studied the peptide. Their program examined short peptides as regulators of aging and neuroendocrine function. Epitalon was one of several compounds produced by that group.
That question is not settled. Cell culture studies have reported increased telomerase activity after treatment, but comparable evidence from controlled human trials is lacking. Any claim about telomere lengthening in people should be treated as unproven.
It has not completed the large, controlled trials required for drug approval in major jurisdictions. Most human reports involve small samples and limited follow-up. As a result, it is sold as a research chemical rather than a licensed pharmaceutical product.
The solid is kept cold, dry and dark, typically at minus twenty degrees Celsius, in a sealed container with desiccant. Dissolved material is kept refrigerated and used promptly. Freezing and thawing a solution repeatedly is avoided because it accelerates degradation.